No patent waiver, but here are the alternatives vaccine makers are offering for Covid shots
Proposal for intellectual property & and patent rights waiver was first introduced at WTO in 2020 by India and South Africa. It has been opposed by US and Europe.
Kairvy Grewal 27 April, 2021 3:25 pm IST
Text Size:
A+
New Delhi: Members of the World Trade Organization (WTO) met last week and continued their resistance towards India and South Africa’s proposal to waive intellectual property (IP) and patent rights on Covid-19 vaccines.
Instead, vaccine makers have offered alternatives such as technology transfer and licences — Serum Institute of India, for example, manufactures Covishield under a licence from AstraZeneca, which developed it with Oxford University researchers — to boost the global immunisation effort.